New Gene-Silencing drug takes first step in human safety trial

NCT ID NCT06494527

Ongoing Disease control Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called RG002C0106 in 30 healthy adults to see if it is safe and how the body processes it. The drug uses RNA interference to silence a gene involved in the immune system's complement pathway. The study is randomized and placebo-controlled, meaning some participants will get the drug and others a dummy shot, but no one knows who gets what.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RG002C0106 (a type of RNA-based drug that silences the complement C3 gene)
What this could lead to: If successful, this could lead to a new treatment for diseases where the complement system is overactive, such as certain kidney or autoimmune conditions.
What could go wrong: This is a very early Phase 1 trial in only 30 healthy people, so it is primarily checking safety, not effectiveness. The drug may not work as hoped or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SAFETY ISSUES

Contacts and locations

Show contact details

Locations

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, 101125, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.